Approach to steroid-dependent and steroid-refractory Crohn's disease

Journal of Pediatric Gastroenterology and Nutrition

Volumn 33, Issue SUPPL. 1, 2001, Pages

  Lichtenstein, G R ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; BUDESONIDE; CORTICOSTEROID; CYCLOSPORIN; ETANERCEPT; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; SALAZOSULFAPYRIDINE; STEROID; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ACNE; ALGORITHM; CLINICAL TRIAL; CONFERENCE PAPER; CROHN DISEASE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; MOON FACE; NAUSEA; PRIORITY JOURNAL; SEDATION; STEROID THERAPY;

EID: 0034791042     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005176-200109001-00005     Document Type: Conference Paper

References (61)

1. National Cooperative Crohn's Disease Study: Results of drug treatment
2. European Cooperative Crohn's Disease study (ECCDS): Results of drug treatment
3. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone
4. Frequency of glucocorticoid resistance and dependency in Crohn's disease
5. Low dose steroids and clinical relapse in Crohn's disease: A controlled trial
6. Corticosteroids for maintaining remission of Crohn's disease (Cochrane Review)
7. National Cooperative Crohn's Disease Study: Adverse reactions to study drugs
8. A comparison of budesonide with prednisolone for active Crohn's disease
9. Prevention and treatment of osteoporosis in patients with inflammatory bowel disease
10. Minimizing complications from systemic glucocorticosteroid use
11. Glucocorticoid-induced osteoporosis: Pathogenesis and management
12. Low bone mineral density in patients with inflammatory bowel disease
13. Management of complications of glucocorticoid therapy
14. Mechanisms of glucocorticoid-induced hypertension
15. Sex hormones and bone metabolism in postmenopausal rheumatoid arthritis treated with two different glucocorticoids
16. Cortisol-induced suppression of plasma testosterone in normal adult males
17. Effect of glucocorticoids on plasma testosterone in men
18. Corticosteroid treatment for inflammatory bowel disease in pediatric patients increases ocular pressure
19. Use of inhaled corticosteroids and the risk of cataracts
20. Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease
21. Oral budesonide as maintenance treatment for Crohn's disease: A placebo-controlled, dose-ranging study
22. Budesonide prolongs time to relapse in ileal and ileo-cecal Crohn's disease
23. Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's disease
24. Low-dose budesonide treatment for prevention of postoperative recurrence of Crohn's disease: A multicentre randomized placebo-controlled trial
25. Oral budesonide as maintenance therapy in Crohn's disease-results of a 12-month stud. Global Budesonide Study Group
26. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease (Cochrane Review)
27. Controlled trial of azathioprine in Crohn's disease
28. Treatment of Crohn's disease with azathioprine: A controlled evaluation
29. Treatment of Crohn's disease with 6-mercaptopurine
30. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease
31. A controlled double blind study of azathioprine in the management of Crohn's disease
32. Azathioprine in the treatment of children with inflammatory bowel disease
33. Long-term 6-mercaptopurine treatment in adolescents with Crohn's disease
34. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease
35. Azathioprine or 6-mercaptopurine for inflammatory bowel disease: Do risks outweigh benefits?
36. Methotrexate for the treatment of Crohn's disease
37. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease
38. European trial of cyclosporine in chronic active Crohn's disease: A 12-month study
39. Low-dose cyclosporine for the treatment of Crohn's disease
40. Ireland Oral cyclosporin for chronic active Crohn's disease A, the Cyclosporin Study Group of Great Britain, multicentre controlled trial
41. A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease
42. A critical review of cyclosporine therapy in inflammatory bowel disease
43. Committee for the International Kidney Biopsy Registry of Cyclosporine in Autoimmune Disease Risk factors for cyclosporine-induced nephropathy in patients with autoimmune disease N Engl J Med
44. Intravenous cyclosporin in ulcerative colitis: A five-year experience
45. Efficacy of cyclosporine in treatment of fistula of Crohn's disease
46. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease
47. Infliximab for the treatment of fistulas in patients with Crohn's disease
48. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (Infliximab) to maintain remission in Crohn's disease
49. Infliximab in Crohn's disease: First anniversary clinical experience
50. Infliximab for Crohn's disease in clinical practice at the Mayo clinic: The first 100 patients
51. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease
52. Use of infliximab in the treatment of Crohn's disease in children and adolescents
53. Long term safety of infliximab
54. A randomized, double-blind, placebo-controlled, multi-center trial of the engineered human antibody to TNF (CDP571) for steroid sparing and maintenance of remission in patients with steroid-dependent Crohn's disease
55. Etanercept (TNF receptor fusion protein, Enbrel®) is effective and well tolerated in active refractory Crohn's disease: Results of a single center pilot trial
56. A randomized, double-blind, placebo-controlled trial of subcutaneous etanercept (p75 soluble tumor necrosis factor: FC fusion protein) in the treatment of moderate to severe Crohn's disease
57. Thalidomide therapy for patients with refractory Crohn's disease: An open-label trial
58. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease
59. Nutrition and inflammatory bowel disease
60. Meta-analysis of enteral nutrition as a primary treatment of active Crohn's disease
61. The nutritional response to home enternal nutrition in childhood